Accessibility Menu
ArriVent BioPharma logo

ArriVent BioPharma(NASDAQ) AVBP

Current Price$27.85
Market Cap$1.31BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)+41%
5 YearN/A
1 Year+28%
1 Month-11%
ArriVent BioPharma last closing stock price
MetricPriceDate
Last closeUSD 28.222026-07-20
ArriVent BioPharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-16.11%USD 33.642026-07-13
1 month-11.09%USD 31.742026-06-18
3 month-8.91%USD 30.982026-04-21
Year to date+40.26%USD 20.122025-12-31
1 year+27.98%USD 22.052025-07-18
Since inception+41.1%USD 20.002024-01-26

ArriVent BioPharma Financials at a Glance

Market Cap

$1.31BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$145.24M

EPS (TTM)

-$3.53

P/E Ratio

-7.99

Dividend

$0.00

Beta (Volatility)

1.00 (Average)

Price

$27.85

Volume

22,601

Open

$28.25

Previous Close

$28.22

Daily Range

$27.45 - $28.48

52-Week Range

$16.10 - $35.83

Estimated Earnings Date

Aug 10, 2026

AVBP News

Foolcom-Featured.png

ArriVent Posts Wider Loss in Fiscal Q2

Motley Fool Markets TeamAug 11, 2025

AVBP: Motley Fool Moneyball Superscore

66

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ArriVent BioPharma

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. With a commitment to addressing unmet medical needs, the company emphasizes precision medicine approaches targeting genetic mutations in non-small cell lung cancer (NSCLC) and other solid tumors. Its lead development candidate, furmonertinib, is being evaluated for its potential to treat uncommon epidermal growth factor receptor (EGFR) mutations, offering hope for patients with limited treatment options.

Products and Services

Furmonertinib: An investigational EGFR mutant-selective tyrosine kinase inhibitor for treating NSCLC with uncommon EGFR mutations.

Next-generation antibody drug conjugates (ADCs) for targeted cancer treatment.

What Makes ArriVent BioPharma, Inc. Special

ArriVent BioPharma’s competitive edge lies in its focus on innovative oncology therapeutics targeting specific genetic mutations, supported by a seasoned leadership team experienced in drug development and commercialization. Their strategic collaborations and in-licensing approach further enhance their pipeline and potential for global success.

Five Things You Need to Know

ArriVent BioPharma is dedicated to developing differentiated medicines to meet the unmet needs of cancer patients.

The company’s lead candidate, furmonertinib, is being tested in pivotal Phase 3 trials targeting unusual EGFR mutations.

Furmonertinib has shown promising interim data in early clinical trials, specifically in patients with NSCLC exon 20 insertions.

ArriVent BioPharma is leveraging collaborations with academic, clinical, and commercial entities to advance their pipeline.

With a strategic emphasis on global expansion and licensing, ArriVent BioPharma aims to enhance its presence in the oncology therapeutics market.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

77

CEO

Zheng Bin Yao, PhD

Website

www.arrivent.com

Headquarters

Newtown Square, PA 19073, US

AVBP Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-48.98%

Return on Capital

-57.78%

Return on Assets

-41.58%

Earnings Yield

-12.52%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.31BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

46.57M

Volume

22.60K

Avg. Volume

555.06K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$156.87M

EBITDA

-$145.24M

Operating Cash Flow

-$134.47M

Capital Expenditure

$0.00

Free Cash Flow

-$134.47M

Cash & ST Invst.

$326.38M

Total Debt

$419.00K

ArriVent BioPharma Performance Analysis

ArriVent BioPharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
ArriVent BioPharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
ArriVent BioPharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.10-28.5%
20232023-12-31USD -2.0787.9%
20242024-12-31USD -2.3915.4%
20252025-12-31USD -4.3281.1%
ArriVent BioPharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3052.6%
Q32025-09-307.8%
Q42025-12-31-1.2%
Q12026-03-31-14.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.31BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$17.07M

N/A

Employees

77

N/A

Net Income

-$43.32M

+32.7%

EBITDA

-$43.32M

+32.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$326.38M

+85.4%

Total Debt

$419.00K

+203.6%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$320.00K

N/A

Short Term Debt

$99.00K

-28.3%

Return on Assets

-41.58%

N/A

Return on Invested Capital

-48.37%

N/A

Free Cash Flow

-$41.89M

+38.4%

Operating Cash Flow

-$41.89M

+38.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MGTXMeiraGTx Holdings plc
$12.49+2.25%
REPLReplimune Group, Inc.
$10.87+3.43%
IOVAIovance Biotherapeutics, Inc.
$5.24+4.28%
MBXMBX Biosciences, Inc. Common Stock
$59.56-0.96%

Trending Stocks

Symbol / CompanyPricePrice Chg
MARAMara Holdings
$12.40+0.06%
AALAmerican Airlines Group
$15.28+0.01%
TET1 Energy Inc.
$6.17+0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.22-0.06%

Questions About AVBP

What is the current price of ArriVent BioPharma?

ArriVent BioPharma is trading at $27.85 per share.

What is the 52-week range for ArriVent BioPharma?

Over the past 52 weeks, ArriVent BioPharma has traded between $16.10 and $35.83.

How much debt does ArriVent BioPharma have?

As of the most recent reporting period, ArriVent BioPharma reported total debt of $419.00K.

How much cash does ArriVent BioPharma have on hand?

ArriVent BioPharma reported $62.10M in cash and cash equivalents in its most recent financial results.

What is ArriVent BioPharma’s dividend yield?

ArriVent BioPharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services